S100P and carcinoma: S100 family proteins including S100A1‐16, S100B, and S100P were summarized based on the review of Bresnick et al.[12] According to the principles of normalization cancer immunotherapy,[49] molecular targets should meet two conditions for potential immunotherapy: specific expression in carcinoma cells and inhibition of TIICs infiltration.